Bioventus Inc. (BVS) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BVS SEC filings page.
Bioventus Inc. (BVS) reported $581.8M in revenue over the twelve months to Jun 27, 2026, up 3.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Bioventus’s 2025 turnaround came with nearly flat sales, showing that expense control and cash conversion—not volume—changed the business economics.
Revenue was essentially flat from FY2024 to FY2025, yet operating margin swung from-2.7% to9.5% . Because gross margin barely moved, the turnaround points to lower operating expenses rather than a major change in revenue mix.
Operating cash flow rose from
Debt fell from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Bioventus Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Bioventus Inc. has an operating margin of 9.5%, meaning the company retains $10 of operating profit per $100 of revenue. This results in a moderate score of 31/100, indicating healthy but not exceptional operating efficiency. This is up from -2.6% the prior year.
Bioventus Inc.'s revenue declined 0.9% year-over-year, from $573.3M to $568.1M. This contraction results in a growth score of 51/100.
Bioventus Inc. has elevated debt relative to equity (D/E of 1.52), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 29/100, reflecting increased financial risk.
Bioventus Inc.'s current ratio of 1.70 indicates adequate short-term liquidity, earning a score of 50/100. The company can meet its near-term obligations, though with limited headroom.
Bioventus Inc. has a free cash flow margin of 12.7%, earning a moderate score of 61/100. The company generates positive cash flow after capital investments, but with room for improvement.
Bioventus Inc.'s ROE of 12.3% shows moderate profitability relative to equity, earning a score of 30/100. This is up from -24.4% the prior year.
Bioventus Inc. scores 1.82, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($926.2M) relative to total liabilities ($455.1M). This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Bioventus Inc. passes 8 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), all 2 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Bioventus Inc. generates $3.28 in operating cash flow ($74.7M OCF vs $22.7M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Bioventus Inc. earns $2.04 in operating income for every $1 of interest expense ($54.0M vs $26.5M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.
Key Financial Metrics
Earnings & Revenue
Bioventus Inc. generated $153.2M in revenue in Q2 2026. This represents an increase of 3.8% from the same quarter a year earlier. Against the prior quarter it is up 16.0%.
Bioventus Inc.'s EBITDA was $20.2M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 1.8% from the same quarter a year earlier. Against the prior quarter it is up 2.8%.
Bioventus Inc. reported $33.4M in net income in Q2 2026. This represents an increase of 348.3% from the same quarter a year earlier. Against the prior quarter it is up 974.2%.
Bioventus Inc. earned $0.47 per diluted share (EPS) in Q2 2026. This represents an increase of 327.3% from the same quarter a year earlier. Against the prior quarter it is up 1075.0%.
Cash & Balance Sheet
Bioventus Inc. generated $18.9M in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 25.1% from the same quarter a year earlier. Against the prior quarter it is up 126.2%.
Bioventus Inc. held $29.5M in cash against $229.7M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Bioventus Inc.'s gross margin was 69.0% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 0.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.2 percentage points.
Bioventus Inc.'s operating margin was 12.5% in Q2 2026, reflecting core business profitability. That is unchanged from the same quarter a year earlier. Against the prior quarter it is up 6.1 percentage points.
Bioventus Inc.'s net profit margin was 21.8% in Q2 2026, showing the share of revenue converted to profit. This is up 16.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 19.5 percentage points.
Bioventus Inc.'s ROE was 14.6% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 10.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 13.0 percentage points.
Capital Allocation
Bioventus Inc. invested $3.2M in research and development in Q2 2026. That is unchanged from the same quarter a year earlier. Against the prior quarter it is up 28.6%.
Bioventus Inc. invested $960K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 40.6% from the same quarter a year earlier. Against the prior quarter it is up 67.2%.
Not reported for Q2 2026.
BVS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $153.2M+3.8% | $132.1M+6.6% | $157.9M+2.8% | $138.7M-0.2% | $147.7M-2.4% | $123.9M-4.3% | $153.6M+13.5% | $139.0M+15.0% |
| Cost of Revenue | $47.5M+4.3% | $41.3M+1.2% | $49.1M-3.7% | $44.4M-2.2% | $45.6M-4.2% | $40.8M-0.6% | $51.0M+3.8% | $45.4M+8.3% |
| Gross Profit | $105.7M+3.5% | $90.8M+9.3% | $108.8M+6.0% | $94.2M+0.7% | $102.1M-1.5% | $83.1M-6.0% | $102.7M+19.0% | $93.6M+18.6% |
| R&D Expenses | $3.2M0.0% | $2.5M-18.1% | $3.0M-8.1% | $2.9M-23.9% | $3.2M-24.7% | $3.0M+14.6% | $3.3M+0.3% | $3.8M+27.5% |
| SG&A Expenses | $82.7M+4.6% | $78.3M+6.6% | $82.8M-4.7% | $78.7M-3.5% | $79.1M-18.2% | $73.5M-6.7% | $86.9M+10.9% | $81.5M+16.7% |
| Operating Income | $19.1M+4.1% | $8.4M+72.8% | $19.5M+153.0% | $11.3M+208.5% | $18.4M+158.4% | $4.9M-1.2% | $7.7M+561.2% | $3.6M+50.8% |
| EBITDA | $20.2M+1.8% | $19.6M+17.3% | $51.8M+25.3% | $12.7M+121.5% | $19.8M+167.4% | $16.7M+0.1% | $41.3M+10.4% | $5.7M+20.6% |
| Interest Expense | $4.1M-45.7% | $4.3M-42.4% | $5.3M-41.0% | $6.2M-35.2% | $7.5M-24.5% | $7.5M-27.4% | $9.0M-12.5% | $9.5M-5.8% |
| Income Tax | -$20.9M-2107.4% | $571K+701.1% | -$3.2M-677.3% | $664K+12.7% | $1.0M+114.2% | -$95K-110.5% | $550K+173.3% | $589K-1.8% |
| Net Income | $33.4M+348.3% | $3.1M+218.1% | $14.8M+3902.8% | $3.2M+161.1% | $7.5M+129.0% | -$2.6M+46.1% | -$388K+93.6% | -$5.2M+29.3% |
| EPS (Basic) | $0.49+345.5% | $0.05+225.0% | $0.22 | $0.05+162.5% | $0.11+127.5% | -$0.04+50.0% | $0.00+100.0% | -$0.08+33.3% |
| EPS (Diluted) | $0.47+327.3% | $0.04+200.0% | $0.21 | $0.05+162.5% | $0.11+127.5% | -$0.04+50.0% | $0.00+100.0% | -$0.08+33.3% |
| Diluted Shares (Avg) | 71M+3.4% | 70M+6.1% | N/A | 69M+5.5% | 69M+7.0% | 66M+4.1% | N/A | 65M+3.9% |
BVS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $673.3M-4.7% | $650.5M-5.9% | $683.6M-6.1% | $701.6M-8.8% | $706.8M-10.8% | $691.4M-12.9% | $728.0M-10.2% | $769.5M-5.1% |
| Current Assets | $257.5M-6.4% | $249.8M+0.2% | $272.8M-1.0% | $280.9M-6.0% | $275.2M-10.9% | $249.4M-6.2% | $275.6M+2.8% | $298.7M+19.7% |
| Cash & Equivalents | $29.5M-10.5% | $35.8M+57.2% | $51.2M+23.2% | $42.2M-2.1% | $32.9M+2.9% | $22.8M-9.4% | $41.6M+12.5% | $43.1M+60.6% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $79.8M-17.3% | $83.2M-11.5% | $82.2M-11.1% | $96.3M+6.9% | $96.5M+10.1% | $94.0M-3.1% | $92.5M+1.3% | $90.0M-7.7% |
| Accounts Receivable | $138.4M+4.6% | $120.5M+2.1% | $128.3M+0.7% | $130.4M+7.0% | $132.4M-3.6% | $118.1M-5.9% | $127.4M+3.7% | $121.9M+8.0% |
| Long-Term Investments | $3.5M+107.9% | $2.1M+19.7% | $2.3M+21.2% | $2.3M+17.6% | $1.7M-19.2% | $1.8M-45.3% | $1.9M-39.8% | $1.9M-71.8% |
| Goodwill | $7.5M0.0% | $7.5M0.0% | $7.5M0.0% | $7.5M0.0% | $7.5M0.0% | $7.5M0.0% | $7.5M0.0% | $7.5M0.0% |
| Total Liabilities | $395.9M-21.7% | $416.3M-17.7% | $455.1M-16.1% | $494.3M-15.2% | $505.5M-16.2% | $505.9M-12.3% | $542.4M-8.0% | $582.7M-0.3% |
| Current Liabilities | $152.5M-17.9% | $148.1M-15.3% | $160.4M-23.8% | $161.8M-23.5% | $185.7M-19.8% | $174.8M+0.8% | $210.4M+19.9% | $211.5M+31.5% |
| Non-Current Liabilities | $243.5M-23.9% | $268.2M-19.0% | $294.7M-11.2% | $332.6M-10.4% | $319.8M-13.9% | $331.2M-17.9% | $332.0M-19.9% | $371.2M-12.4% |
| Long-Term Debt | $229.7M-22.9% | $253.3M-17.9% | $279.0M-9.5% | $311.3M-9.8% | $297.9M-13.6% | $308.6M-13.2% | $308.3M-16.0% | $345.0M-8.0% |
| Total Equity | $228.3M+41.6% | $188.9M+27.5% | $184.1M+24.4% | $166.1M+11.7% | $161.2M+6.8% | $148.1M-13.5% | $147.9M-14.8% | $148.7M-16.2% |
| Retained Earnings | -$298.4M+15.4% | -$331.8M+7.9% | -$334.9M+6.4% | -$349.7M+1.5% | -$352.8M-0.8% | -$360.3M-10.5% | -$357.7M-11.2% | -$354.9M-12.5% |
BVS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $19.9M-23.4% | $8.9M+146.2% | $38.0M+96.5% | $30.1M+191.8% | $25.9M+71.1% | -$19.3M-221.9% | $19.3M+86.3% | $10.3M+224.1% |
| Depreciation & Amortization | $1.0M-27.7% | $11.2M-5.6% | $11.7M-5.7% | $1.4M-32.3% | $1.4M-30.3% | $11.9M+0.7% | $12.4M-0.5% | $2.1M-10.9% |
| Stock-Based Compensation | $4.8M+42.0% | $3.3M+35.2% | N/A | $3.2M+27.5% | $3.4M-39.6% | $2.4M-19.3% | N/A | $2.5M |
| Capital Expenditures | $960K+40.6% | $574K-30.5% | $580K+1.0% | $473K+639.1% | $683K+787.0% | $826K+183.8% | $574K+55.6% | $64K-96.9% |
| Free Cash Flow | $18.9M-25.1% | $8.4M+141.5% | $37.4M+99.4% | $29.6M+189.0% | $25.3M+67.4% | -$20.2M-220.2% | $18.7M+87.4% | $10.3M+199.0% |
| Investing Cash Flow | -$2.5M-79.7% | -$574K+30.5% | -$580K-102.4% | -$473K-639.1% | -$1.4M-1677.9% | -$826K+17.4% | $24.1M+4178.5% | -$64K+96.9% |
| Financing Cash Flow | -$23.4M-59.8% | -$23.1M-2543.9% | -$28.4M+33.6% | -$20.0M-5618.5% | -$14.7M-86.9% | $947K+122.3% | -$42.9M-306007.1% | $362K-95.6% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BVS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.0%-0.2pp | 68.7%+1.7pp | 68.9%+2.1pp | 68.0%+0.6pp | 69.1%+0.6pp | 67.0%-1.2pp | 66.8%+3.1pp | 67.3%+2.0pp |
| Operating Margin | 12.5%0.0pp | 6.4%+2.4pp | 12.3%+7.3pp | 8.1%+5.5pp | 12.4%+33.3pp | 3.9%+0.1pp | 5.0%+4.1pp | 2.6%+0.6pp |
| Net Margin | 21.8%+16.8pp | 2.4%+4.5pp | 9.3%+9.6pp | 2.3%+6.0pp | 5.1%+22.0pp | -2.1%+1.7pp | -0.3%+4.3pp | -3.7%+2.3pp |
| Return on Equity | 14.6%+10.0pp | 1.7%+3.4pp | 8.0%+8.3pp | 1.9%+5.4pp | 4.6%+21.6pp | -1.8%+1.1pp | -0.3%+3.2pp | -3.5%+0.6pp |
| Return on Assets | 5.0%+3.9pp | 0.5%+0.9pp | 2.2%+2.2pp | 0.4%+1.1pp | 1.1%+4.3pp | -0.4%+0.2pp | -0.1%+0.7pp | -0.7%+0.2pp |
| Current Ratio | 1.69+0.2x | 1.69+0.3x | 1.70+0.4x | 1.74+0.3x | 1.48+0.1x | 1.43-0.1x | 1.31-0.2x | 1.41-0.1x |
| Debt-to-Equity | 1.01-0.8x | 1.34-0.7x | 1.52-0.6x | 1.87-0.4x | 1.85-0.4x | 2.080.0x | 2.080.0x | 2.32+0.2x |
| Asset Turnover | 0.230.0x | 0.200.0x | 0.230.0x | 0.200.0x | 0.210.0x | 0.180.0x | 0.210.0x | 0.180.0x |
| FCF Margin | 12.3%-4.8pp | 6.3%+22.6pp | 23.7%+11.5pp | 21.4%+14.0pp | 17.1%+7.1pp | -16.3%-11.4pp | 12.2%+4.8pp | 7.4%+16.0pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Bioventus Inc. BVS | FY2025 | $568.1M | $22.7M | 4.0% | $926.2M | 42/100 |
| Standard BioTools Inc. LAB | FY2025 | $85.3M | -$74.9M | -87.8% | $258.2M | 44/100 |
| Treace Medical Concepts, Inc. TMCI | FY2025 | $212.7M | -$59.0M | -27.7% | $266.6M | 45/100 |
| Surmodics, Inc. SRDX | FY2024 | $126.1M | -$11.5M | -9.2% | $614.5M | — |
| Orthofix Medical Inc. OFIX | FY2025 | $822.3M | -$92.2M | -11.2% | $378.0M | 43/100 |
| Avanos Medical, Inc. AVNS | FY2025 | $701.2M | -$72.9M | -10.4% | $1.2B | 44/100 |
Where Bioventus Inc. Ranks
Frequently Asked Questions
What is Bioventus Inc.'s annual revenue?
Bioventus Inc. (BVS) reported $568.1M in total revenue for fiscal year 2025. This represents a -0.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Bioventus Inc.'s revenue growing?
Bioventus Inc. (BVS) revenue declined by 0.9% year-over-year, from $573.3M to $568.1M in fiscal year 2025.
Is Bioventus Inc. profitable?
Yes, Bioventus Inc. (BVS) reported a net income of $22.7M in fiscal year 2025, with a net profit margin of 4.0%.
What is Bioventus Inc.'s EBITDA?
Bioventus Inc. (BVS) had EBITDA of $101.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Bioventus Inc. have?
As of fiscal year 2025, Bioventus Inc. (BVS) had $51.2M in cash and equivalents against $279.0M in long-term debt.
What is Bioventus Inc.'s gross margin?
Bioventus Inc. (BVS) had a gross margin of 68.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Bioventus Inc.'s operating margin?
Bioventus Inc. (BVS) had an operating margin of 9.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Bioventus Inc.'s net profit margin?
Bioventus Inc. (BVS) had a net profit margin of 4.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Bioventus Inc.'s return on equity (ROE)?
Bioventus Inc. (BVS) has a return on equity of 12.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Bioventus Inc.'s free cash flow?
Bioventus Inc. (BVS) generated $72.1M in free cash flow during fiscal year 2025. This represents a 90.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Bioventus Inc.'s operating cash flow?
Bioventus Inc. (BVS) generated $74.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Bioventus Inc.'s total assets?
Bioventus Inc. (BVS) had $683.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Bioventus Inc.'s capital expenditures?
Bioventus Inc. (BVS) invested $2.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Bioventus Inc. spend on research and development?
Bioventus Inc. (BVS) invested $12.1M in research and development during fiscal year 2025.
What is Bioventus Inc.'s current ratio?
Bioventus Inc. (BVS) had a current ratio of 1.70 as of fiscal year 2025, which is generally considered healthy.
What is Bioventus Inc.'s debt-to-equity ratio?
Bioventus Inc. (BVS) had a debt-to-equity ratio of 1.52 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Bioventus Inc.'s return on assets (ROA)?
Bioventus Inc. (BVS) had a return on assets of 3.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Bioventus Inc.'s P/E ratio?
Bioventus Inc. (BVS) trades at 17.0x earnings, its market capitalization divided by net income of $54.5M net income, trailing 12 months to June 27, 2026. The market capitalization is $926.2M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Bioventus Inc.'s price-to-sales ratio?
Bioventus Inc. (BVS) trades at 1.6x sales, its market capitalization divided by revenue of $581.8M revenue, trailing 12 months to June 27, 2026. The market capitalization is $926.2M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Bioventus Inc.'s Altman Z-Score?
Bioventus Inc. (BVS) has an Altman Z-Score of 1.82, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Bioventus Inc.'s Piotroski F-Score?
Bioventus Inc. (BVS) has a Piotroski F-Score of 8 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Bioventus Inc.'s earnings high quality?
Bioventus Inc. (BVS) has an earnings quality ratio of 3.28x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Bioventus Inc. cover its interest payments?
Bioventus Inc. (BVS) has an interest coverage ratio of 2.04x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Bioventus Inc.?
Bioventus Inc. (BVS) scores 42 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.